高级检索
当前位置: 首页 > 详情页

Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China
出处:
ISSN:

关键词: Non-small cell lung cancer Epidermal growth factor receptor Immunohistochemistry Real-time PCR Next-generation sequencing (NGS)

摘要:
Epidermal growth factor receptor (EGFR) is an important gene in the development of lung cancer. Non-small cell lung cancer (NSCLC) is the most common lung cancer. In the present study, the expression of EGFR in 717 patients with NSCLC was detected by Ventana automatic immunohistochemical technique, and the samples was verified by Real-time PCR, and then the results were compared with the data acquired by next-generation sequencing technology (NGS), which is the high throughput, multiple sites for EGFR gene mutation testing. The expression of Ventana EGFR in 717 cases of NSCLC was detected by immunohistochemistry, and the positive rate was 60.70 % (435 / 717). The mutation rate of EGFR was 57.60 % (413/717). The coincidence rate of Ventana EGFR immunohistochemical assay and Real-time PCR assay reached 94.94 %, and the two had high consistency. The coincidence rate of Ventana EGFR immunohistochemical assay and NGS were high correlation. Based on these results, Ventana EGFR automatic immunohistochemical detection has high accuracy, simple operation process, low price and easy interpretation. It can be used as the preferred method for EGFR detection.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 病理学
JCR分区:
出版当年[2020]版:
Q2 PATHOLOGY
最新[2024]版:
Q2 PATHOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China [*1]Departments of Pathology, The Fourth Hospital of Hebei Medical University, No.12, Jiankang Road, Shijiazhuang, 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma [2]Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients [3]IMPACT OF NEXT-GENERATION SEQUENCING (NGS) FOR PRIMARY ENDOCRINE RESISTANCE ON BREAST CANCER PATIENTS [4]Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial. [5]A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation [6]Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial. [7]A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. [8]Value of pre-therapy F-18-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer [9]Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy [10]Transformation from non-small cell lung cancer to small cell lung cancer: A report of clinicopathological characteristics and prognoses.

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号